138 related articles for article (PubMed ID: 8261579)
1. Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer.
Levêque D; Quoix E; Dumont P; Massard G; Hentz JG; Charloux A; Jehl F
Cancer Chemother Pharmacol; 1993; 33(2):176-8. PubMed ID: 8261579
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography.
Levêque D; Jehl F; Quoix E; Monteil H
Xenobiotica; 1993 Nov; 23(11):1325-33. PubMed ID: 8310715
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin.
Levêque D; Jehl F; Quoix E; Breillout F
J Clin Pharmacol; 1992 Dec; 32(12):1096-8. PubMed ID: 1336784
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.
Jehl F; Quoix E; Leveque D; Pauli G; Breillout F; Krikorian A; Monteil H
Cancer Res; 1991 Apr; 51(8):2073-6. PubMed ID: 1849042
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group.
Furuse K; Kubota K; Kawahara M; Ogawara M; Kinuwaki E; Motomiya M; Nishiwaki Y; Niitani H; Sakuma A
Lung Cancer; 1994 Dec; 11(5-6):385-91. PubMed ID: 7704495
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer.
Depierre A; Lemarie E; Dabouis G; Garnier G; Jacoulet P; Dalphin JC
Am J Clin Oncol; 1991 Apr; 14(2):115-9. PubMed ID: 1851385
[TBL] [Abstract][Full Text] [Related]
7. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S
J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
[TBL] [Abstract][Full Text] [Related]
8. Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.
van Tellingen O; Kuijpers AV; Beijnen JH; Nooijen WJ; Bult A
Invest New Drugs; 1993; 11(2-3):141-50. PubMed ID: 8262726
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of vinorelbine.
Levêque D; Jehl F
Clin Pharmacokinet; 1996 Sep; 31(3):184-97. PubMed ID: 8877249
[TBL] [Abstract][Full Text] [Related]
10. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.
Goa KL; Faulds D
Drugs Aging; 1994 Sep; 5(3):200-34. PubMed ID: 7803948
[TBL] [Abstract][Full Text] [Related]
11. Biliary elimination and pharmacokinetics of vinorelbine in micropigs.
Levêque D; Merle-Melet M; Bresler L; Didelot JP; Aymard JP; Wihlm J; Jehl F
Cancer Chemother Pharmacol; 1993; 32(6):487-90. PubMed ID: 8258199
[TBL] [Abstract][Full Text] [Related]
12. Vinorelbine: a novel vinca alkaloid.
Toso C; Lindley C
Am J Health Syst Pharm; 1995 Jun; 52(12):1287-304; quizz 1340-1. PubMed ID: 7656116
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice.
Tsuruo T; Inaba M; Tashiro T; Yamori T; Ohnishi Y; Ashizawa T; Sakai T; Kobayashi S; Gomi K
Anticancer Drugs; 1994 Dec; 5(6):634-40. PubMed ID: 7888700
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture.
Gomi K; Ohno H; Nomura K; Okabe M; Kobayashi K; Niitani H
Jpn J Cancer Res; 1992 May; 83(5):532-9. PubMed ID: 1618703
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
Evans WK; Le Chevalier T
Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
[TBL] [Abstract][Full Text] [Related]
16. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T
Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
[TBL] [Abstract][Full Text] [Related]
17. RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer.
Stuckler D; Singhal J; Singhal SS; Yadav S; Awasthi YC; Awasthi S
Cancer Res; 2005 Feb; 65(3):991-8. PubMed ID: 15705900
[TBL] [Abstract][Full Text] [Related]
18. The clinical pharmacokinetics of vinorelbine (Navelbine).
Wargin WA; Lucas VS
Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
[TBL] [Abstract][Full Text] [Related]
19. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
20. Vinorelbine for non-small cell lung cancer.
Piccirillo MC; Daniele G; Di Maio M; Bryce J; De Feo G; Del Giudice A; Perrone F; Morabito A
Expert Opin Drug Saf; 2010 May; 9(3):493-510. PubMed ID: 20350282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
